SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda